| Code | CSB-RA855470MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to SSGJ-626, targeting CLEC4C (C-type lectin domain family 4 member C), also known as BDCA-2 or CD303. CLEC4C is a type II transmembrane receptor predominantly expressed on plasmacytoid dendritic cells (pDCs), where it functions as an inhibitory receptor that regulates type I interferon production upon engagement. This protein plays a critical role in immune regulation and self-tolerance, with its expression pattern making it a valuable marker for identifying and studying pDCs in various immunological contexts. Dysregulation of CLEC4C-mediated signaling has been implicated in autoimmune disorders, viral infections, and hematological malignancies, particularly blastic plasmacytoid dendritic cell neoplasm (BPDCN).
The reference antibody SSGJ-626 has been utilized in research settings to investigate pDC biology, immune responses, and disease pathogenesis. This biosimilar antibody provides researchers with a reliable tool for exploring CLEC4C function, examining pDC involvement in immune-mediated diseases, and advancing understanding of innate immunity mechanisms. It supports diverse experimental approaches in immunology and oncology research.
There are currently no reviews for this product.